Esopan DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a dopamine D2 receptor antagonist, facilitates gastric motility and enhances esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing symptomatic relief in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic action of these agents addresses both acid-related mucosal damage and motility disturbances, improving overall gastrointestinal function. Esopan DSR Capsule is indicated for patients requiring both acid suppression and prokinetic therapy, particularly those with refractory GERD or functional dyspepsia. It is generally well tolerated; however, caution is advised in patients with known hypersensitivity to either component, underlying cardiac arrhythmias, or hepatic impairment. Administration should follow medical prescription, with dosage adjustments based on clinical response. Regular monitoring is recommended to assess therapeutic efficacy and detect potential adverse effects. This combination therapy offers an effective approach to managing complex upper gastrointestinal conditions by targeting multiple pathophysiological mechanisms.